Plant Name: Glycyrrhiza uralensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NMUR2; | |
| ADORA3; ADRA2C; ADRA2A; GPBAR1; HCAR2; | |
| ALPI; ALPL; RECQL; TDP1; PLA2G1B; BLM; CTDSP1; P4HB; PKM; HPGD; HSD11B1; HSD11B2; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; PGD; ALDH1A1; ALOX12; GFER; AKR1B10; NOX4; USP2; BRCA1; TNKS; PARP1; TNKS2; APEX1; POLB; CES2; AGL; AOX1; | |
| MGAM; ACHE; GAA; BCHE; | |
| PTPN1; CDC25B; PTPN11; PTPN2; | |
| PDE5A; | |
| CFTR; | |
| BCL2; | |
| MET; AKT1; CSNK2A1; DAPK1; SYK; FLT3; ABL1; CDK2; GSK3B; CDK6; MAPK1; MAPK14; EGFR; PIM1; ATM; PTK2B; | |
| CA3; CA14; CA5B; CA5A; CA1; CA12; CA9; CA7; CA4; CA6; CA2; | |
| AR; | |
| ESRRB; ESRRA; | |
| ESR1; ESR2; | |
| NR1H4; | |
| KDM4E; | |
| MAOA; ALDH2; ALOX5; PTGS2; TYR; XDH; | |
| CASP7; CASP1; | |
| PLG; | |
| AHR; HIF1A; NFKB1; TP53; | |
| KMT2A; | |
| FUT7; | |
| ABCC1; ABCG2; | |
| SLCO1B3; SLCO1B1; | |
| LMNA; MCL1; MAPT; F3; HBB; THPO; SIGMAR1; HTT; RAB9A; NPC1; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | CES2 | Carboxylesterase 2 | O00748 | CHEMBL3180 |
| Enzyme_unclassified | AGL | Glycogen debranching enzyme | P35573 | CHEMBL5272 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | P80365 | CHEMBL3746 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Phosphodiesterase 5 | PDE5A | Phosphodiesterase 5A | O76074 | CHEMBL1827 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | CDK2 | Cyclin-dependent kinase 2 | P24941 | CHEMBL301 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | ATM | Serine-protein kinase ATM | Q13315 | CHEMBL3797 |
| Protein Kinase | PTK2B | Protein tyrosine kinase 2 beta | Q14289 | CHEMBL5469 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Protein Phosphatase | PTPN11 | Protein-tyrosine phosphatase 2C | Q06124 | CHEMBL3864 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Serine protease | PLG | Plasminogen | P00747 | CHEMBL1801 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.552E-13 | 1.112E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HBB, NOX4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.363E-11 | 1.267E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HBB, NOX4, PTGS2, TBXAS1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.509E-11 | 1.772E-08 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 2.263E-10 | 4.879E-08 | AR, CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD11B2, HSD17B1, NPC1, NR1H4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.622E-10 | 8.987E-08 | ALPI, AR, BLM, BRCA1, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, KMT2A, NR1H4, PARP1, PTPN1, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.677E-09 | 4.350E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 6.299E-09 | 9.268E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 4.497E-08 | 5.410E-06 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.041E-07 | 2.009E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 2.961E-07 | 2.744E-05 | ABL1, ATM, BCL2, BRCA1, MCL1, POLB, TP53 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.947E-07 | 3.493E-05 | ABCC1, ADRA2A, CA2, CA4, CA9, EGFR, HPGD, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 4.069E-07 | 3.587E-05 | ABL1, ACHE, CASP1, CFTR, EGFR, HCAR2, HIF1A, MAPK14, NR1H4, PLA2G1B, SYK |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 4.159E-07 | 3.637E-05 | ABL1, AGL, AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, AOX1, AR, BCL2, BLM, CA1, CA2, CA3, CA7, CASP1, CASP7, CDC25B, CDK2, CDK6, CFTR, CSNK2A1, FLT3, GFER, GSK3B, HBB, HIF1A, HPGD, HSD17B1, HTT, KMT2A, LMNA, MAPK1, MAPK14, MAPT, MCL1, NFKB1, PDE5A, PGD, PIM1, PKM, PLA2G1B, PTK2B, PTPN1, PTPN11, PTPN2, RAB9A, SMN1, SMN2, SYK, TNKS, TNKS2, TP53, TYR, XDH |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 6.997E-07 | 5.750E-05 | ABL1, ATM, GSK3B, MAPT, MCL1, PARP1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 8.205E-07 | 6.545E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 8.205E-07 | 6.545E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 9.503E-07 | 7.470E-05 | AKT1, BCL2, MAPT, PTPN1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.079E-06 | 8.186E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.364E-06 | 1.002E-04 | AKT1, ATM, BCL2, CDK2, GSK3B, MAPK1, MAPK14, SYK, TNKS |
| MF | GO:0005488; binding | GO:0051287; NAD binding | 2.321E-06 | 1.579E-04 | ALDH1A1, ALDH2, AOX1, HPGD, HSD11B2, PARP1 |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 2.789E-06 | 1.863E-04 | ABL1, AKT1, APEX1, BCL2, CA5A, CA5B, CASP1, CYP1A1, CYP1B1, CYP2D6, ESR2, GFER, GSK3B, HSD17B10, MAOA, MAPK1, MAPK14, MCL1, NFKB1, NOX4, PARP1, PKM, PTPN11, TP53 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 3.303E-06 | 2.134E-04 | ADORA3, AR, ATM, BCHE, BCL2, CDK6, CYP1B1, KMT2A, LMNA, NOX4, PDE5A, PLG, PTGS2, PTK2B, PTPN2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 5.344E-06 | 3.297E-04 | AKT1, BCL2, HIF1A, LMNA, P4HB, PTGS2, TP53 |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 6.257E-06 | 3.753E-04 | ABL1, ACHE, ADRA2A, APEX1, ATM, CSNK2A1, EGFR, ESRRB, FLT3, MAPT, P4HB, PIM1, PKM, PLG, PTK2B, PTPN1, PTPN11, PTPN2, SYK, TSHR |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 6.771E-06 | 3.995E-04 | AKT1, EGFR, HBB, PTGS2, PTK2B |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 6.865E-06 | 4.019E-04 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 7.716E-06 | 4.468E-04 | ABL1, ALOX12, BRCA1, CYP1B1, F3, HIF1A, PTGS2, PTK2B |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 8.162E-06 | 4.702E-04 | BCL2, CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR, HSD11B1, HSD11B2, HSD17B2, NOX4, PTGS2, RAB9A, SIGMAR1, TBXAS1 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 8.424E-06 | 4.802E-04 | AKT1, ATM, CDK2, CDK6, CSNK2A1, DAPK1, EGFR, GSK3B, MAPK1, MAPK14, PIM1, PTK2B, SYK |
| BP | GO:0032502; developmental process | GO:0048538; thymus development | 8.606E-06 | 4.893E-04 | ABL1, ATM, BCL2, MAPK1, TYR |
| MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 9.306E-06 | 5.263E-04 | AKT1, EGFR, ESR1 |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 9.659E-06 | 5.435E-04 | ABL1, AKT1, HIF1A, MAPK14, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.196E-05 | 6.563E-04 | AKT1, BCL2, CSNK2A1, GSK3B, MAPK1, TNKS |
| BP | GO:0032501; multicellular organismal process | GO:0060020; Bergmann glial cell differentiation | 1.482E-05 | 7.935E-04 | ABL1, MAPK1, PTPN11 |
| BP | GO:0009987; cellular process | GO:1903376; regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | 1.482E-05 | 7.935E-04 | HIF1A, MCL1, PARP1 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.623E-05 | 8.579E-04 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, AOX1, BCL2, BLM, FLT3, HPGD, KMT2A, MAPT, MCL1, NFKB1, PTGS2, TYR, XDH |
| MF | Unclassified; | GO:0032403; protein complex binding | 1.623E-05 | 8.579E-04 | ABL1, ACHE, ADRA2A, APEX1, ATM, EGFR, ESRRB, FLT3, P4HB, PKM, PLG, PTK2B, PTPN1, PTPN11, PTPN2, SYK, TSHR |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 1.732E-05 | 9.025E-04 | AR, BRCA1, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 1.792E-05 | 9.289E-04 | CFTR, CYP19A1, EGFR, HCAR2, HIF1A, NR1H4, PTPN11 |
| BP | GO:0008152; metabolic process | GO:0050731; positive regulation of peptidyl-tyrosine phosphorylation | 1.802E-05 | 9.321E-04 | ABL1, ADRA2A, ADRA2C, FLT3, PTK2B, PTPN1, SYK, TP53 |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 2.040E-05 | 1.036E-03 | AKT1, ATM, BLM, BRCA1, CDK2, CSNK2A1, MAPK14, TP53 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 2.212E-05 | 1.110E-03 | BLM, RECQL, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 2.697E-05 | 1.299E-03 | BRCA1, CYP1B1, HIF1A, PTGS2 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 3.145E-05 | 1.473E-03 | CA2, CA7, CFTR |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 3.697E-05 | 1.706E-03 | AKT1, BCL2, HIF1A, MCL1, PTGS2, PTPN1 |
| BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 4.222E-05 | 1.880E-03 | AOX1, XDH |
| BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 4.222E-05 | 1.880E-03 | EGFR, NMUR2 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 4.222E-05 | 1.880E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.222E-05 | 1.880E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 4.222E-05 | 1.880E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 4.222E-05 | 1.880E-03 | ACHE, BCHE |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.222E-05 | 1.880E-03 | ALOX12, ALOX15 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 4.304E-05 | 1.901E-03 | AR, CYP19A1, ESR1 |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 4.304E-05 | 1.901E-03 | GSK3B, HTT, MAPT |
| MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 4.457E-05 | 1.962E-03 | ABCC1, ABCG2, ATM, HTT, NPC1, SLCO1B1, SLCO1B3 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 4.738E-05 | 2.066E-03 | AKT1, CYP1A2, EGFR, MAPK1 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 5.388E-05 | 2.314E-03 | AHR, CSNK2A1, HIF1A, MAPT |
| BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 6.100E-05 | 2.584E-03 | ADRA2C, AKT1, EGFR, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0019318; hexose metabolic process | 6.549E-05 | 2.753E-03 | AKR1B1, AKT1, ALDH1A1, FUT7, GAA, MAPK14, PKM |
| BP | GO:0009987; cellular process | GO:0007569; cell aging | 6.586E-05 | 2.763E-03 | ATM, BCL2, MAPK14, NOX4, TP53 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 6.694E-05 | 2.800E-03 | ABL1, BCL2, CA2, CA7, HTT, PARP1, PLA2G1B, PTK2B |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 6.879E-05 | 2.859E-03 | ATM, MAPK1, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 7.390E-05 | 3.042E-03 | CYP19A1, HSD17B1, HSD17B2 |
| MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 7.621E-05 | 3.119E-03 | APEX1, BLM, BRCA1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 8.183E-05 | 3.312E-03 | AKT1, ESRRB, HIF1A, NFKB1, PTPN2 |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 8.346E-05 | 3.364E-03 | ADRA2A, AKT1, HIF1A, NOX4, NR1H4, PTPN11, PTPN2 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 8.415E-05 | 3.381E-03 | ADRA2A, ADRA2C, AKT1, MAPK1, PTPN11, SYK |
| BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 9.384E-05 | 3.702E-03 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 9.402E-05 | 3.702E-03 | BLM, GSK3B, HIF1A, HTT, TP53 |
| BP | GO:0008152; metabolic process | GO:0010507; negative regulation of autophagy | 1.006E-04 | 3.934E-03 | AKT1, BCL2, MCL1, MET, NPC1 |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.009E-04 | 3.936E-03 | ADRA2A, ADRA2C, AHR, BCL2, EGFR, HIF1A, MCL1, NFKB1, P4HB, TP53, TTR, TYR |
| BP | GO:0032501; multicellular organismal process | GO:0009791; post-embryonic development | 1.149E-04 | 4.396E-03 | ABL1, ATM, BCL2, CYP1A2, KMT2A |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 1.157E-04 | 4.410E-03 | ALOX15, ESR1, GSK3B, MAPT, MET, PARP1, PTK2B, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 1.164E-04 | 4.417E-03 | CA2, EGFR, SYK |
| BP | GO:0009987; cellular process | GO:0010821; regulation of mitochondrion organization | 1.193E-04 | 4.509E-03 | AKT1, BCL2, GSK3B, HIF1A, HTT, LMNA, MAPT, TP53 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.197E-04 | 4.517E-03 | ABCC1, ABCG2, ABL1, AKT1, ATM, BLM, CDK2, CDK6, CFTR, CSNK2A1, DAPK1, EGFR, FLT3, GSK3B, MAPK1, MAPK14, MET, PIM1, PKM, PTK2B, RECQL, SYK, TP53 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.261E-04 | 4.607E-03 | CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0000023; maltose metabolic process | 1.261E-04 | 4.607E-03 | GAA, MGAM |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 1.261E-04 | 4.607E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.261E-04 | 4.607E-03 | CA2, CA7 |
| BP | GO:0019740; nitrogen utilization | GO:0006808; regulation of nitrogen utilization | 1.261E-04 | 4.607E-03 | BCL2, NR1H4 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.261E-04 | 4.607E-03 | GPBAR1, NR1H4 |
| BP | GO:0065007; biological regulation | GO:0051882; mitochondrial depolarization | 1.261E-04 | 4.607E-03 | ABL1, CASP1 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.261E-04 | 4.607E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.261E-04 | 4.607E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.261E-04 | 4.607E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.261E-04 | 4.607E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0032450; maltose alpha-glucosidase activity | 1.261E-04 | 4.607E-03 | GAA, MGAM |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.261E-04 | 4.607E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.261E-04 | 4.607E-03 | GPBAR1, NR1H4 |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 1.391E-04 | 5.007E-03 | AKR1B1, AKT1, EGFR, HPGD, PTGS2 |
| BP | GO:0032501; multicellular organismal process | GO:0048546; digestive tract morphogenesis | 1.426E-04 | 5.097E-03 | BCL2, EGFR, HIF1A |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 1.629E-04 | 5.703E-03 | CYP1A2, EGFR, ESR1, ESRRA, HPGD, PTGS2 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.724E-04 | 6.025E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 1.744E-04 | 6.075E-03 | ACHE, ADORA3, ALOX15, BCL2, CYP1A1, EGFR, TP53 |
| BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 1.749E-04 | 6.075E-03 | AKT1, MAPK14, NR1H4, PTPN11 |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.880E-04 | 6.436E-03 | AKR1B1, AKT1, AR, CFTR, EGFR |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 1.992E-04 | 6.682E-03 | CASP1, CASP7, F3, MAPT, XDH |
| BP | GO:0032502; developmental process | GO:0048638; regulation of developmental growth | 2.054E-04 | 6.865E-03 | ABL1, AKT1, AR, BCL2, MAPK14, MAPT, PIM1, PTPN11, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 2.059E-04 | 6.865E-03 | AKT1, HIF1A, PTK2B |
| BP | GO:0008152; metabolic process | GO:0032928; regulation of superoxide anion generation | 2.059E-04 | 6.865E-03 | EGFR, MAPT, SYK |
| CC | GO:0043226; organelle | GO:0016604; nuclear body | 2.357E-04 | 7.707E-03 | ABL1, AOX1, APEX1, AR, BLM, CDK2, HIF1A, LMNA, MAPK14, MAPT, SMN1, SMN2, TNKS, TP53 |
| BP | GO:0002376; immune system process | GO:0010758; regulation of macrophage chemotaxis | 2.433E-04 | 7.919E-03 | CYP19A1, MAPK14, PTK2B |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.478E-04 | 7.980E-03 | ABL1, EGFR, PTK2B, SYK |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.511E-04 | 7.980E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.511E-04 | 7.980E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 2.511E-04 | 7.980E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 2.511E-04 | 7.980E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.511E-04 | 7.980E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.511E-04 | 7.980E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 2.511E-04 | 7.980E-03 | ALDH1A1, AR |
| MF | GO:0003824; catalytic activity | GO:0004558; alpha-1,4-glucosidase activity | 2.511E-04 | 7.980E-03 | GAA, MGAM |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 2.656E-04 | 8.380E-03 | AKR1B1, AKT1, BCHE, EGFR, HSD17B2, NR1H4, PTGS2, PTK2B, TP53 |
| BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 2.677E-04 | 8.424E-03 | ADRA2A, AKT1, ATM, DAPK1, ESRRB, GSK3B, HIF1A, HTT, PTK2B, PTPN1 |
| BP | GO:0048511; rhythmic process | GO:0007623; circadian rhythm | 2.690E-04 | 8.453E-03 | AHR, EGFR, GSK3B, KMT2A, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0042133; neurotransmitter metabolic process | 2.772E-04 | 8.685E-03 | ACHE, AKT1, BCHE, CYP1B1, MAOA |
| BP | GO:0008152; metabolic process | GO:0045944; positive regulation of transcription from RNA polymerase II promoter | 2.805E-04 | 8.764E-03 | AHR, AKT1, AR, BRCA1, EGFR, ESR1, ESRRA, ESRRB, HIF1A, KMT2A, MAPK14, MET, NFKB1, NR1H4, PARP1, PLA2G1B, TNKS, TP53 |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 2.849E-04 | 8.874E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0008152; metabolic process | GO:0051972; regulation of telomerase activity | 2.914E-04 | 9.039E-03 | ATM, MAPK1, TNKS, TP53 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 3.132E-04 | 9.605E-03 | ABL1, ALOX15, EGFR, NOX4, PTK2B, PTPN11, THPO |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 3.150E-04 | 9.639E-03 | ABL1, ACHE, AKR1B1, APEX1, CA4, EGFR, HTT, NOX4, NPC1, PTK2B, TNKS2, TYR, USP2 |
| BP | GO:0050896; response to stimulus | GO:0043279; response to alkaloid | 3.240E-04 | 9.852E-03 | BCHE, BLM, CASP7, PTK2B, TP53 |
| MF | GO:0005488; binding | GO:0003690; double-stranded DNA binding | 3.269E-04 | 9.915E-03 | AHR, APEX1, AR, EGFR, ESR1, ESR2, ESRRA, ESRRB, HIF1A, KMT2A, NFKB1, NR1H4, PARP1, TDP1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 3.308E-04 | 9.948E-03 | CA2, PTGS2, PTK2B |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.308E-04 | 9.948E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0044247; cellular polysaccharide catabolic process | 3.308E-04 | 9.948E-03 | AGL, GAA, MGAM |
| BP | GO:0008152; metabolic process | GO:0009251; glucan catabolic process | 3.308E-04 | 9.948E-03 | AGL, GAA, MGAM |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.776E-22 | 2.822E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.981E-19 | 1.504E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR, HBB |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 7.830E-15 | 6.089E-12 | ABL1, ATM, CA2, CA7, CFTR, EGFR, HCAR2, HIF1A, HTT, MAPK1, MAPK14, NPC1, NR1H4, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.136E-14 | 1.410E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 5.120E-14 | 2.934E-11 | ABL1, ADRA2A, ATM, BCL2, CA2, CA7, CDK6, CFTR, EGFR, HCAR2, HIF1A, HTT, MAPK1, MAPK14, NPC1, NR1H4, PARP1, PLA2G1B, PTGS2, PTK2B, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.421E-13 | 6.877E-11 | ALOX12, ALOX15, ALOX5, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HBB, TBXAS1, XDH |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.761E-21 | 9.617E-19 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.319E-12 | 4.362E-10 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; HSD11B1; FUT7; ALDH2; HSD17B1; ALOX5; HSD17B2; AOX1; XDH; MGAM; GAA; AGL; PGD; TYR; CYP2C9; PKM; AKR1B10; TBXAS1; CYP1A2; ALDH1A1; CYP1A1; ALPL; ALPI |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 6.150E-11 | 4.141E-09 | ABCC1; BRCA1; PTGS2; EGFR; NFKB1; CDC25B; CDK6; PIM1; ABL1; BCL2; CYP1B1; MAPK1; ATM; TP53; MET; MCL1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 4.201E-09 | 1.455E-07 | GSK3B; FLT3; DAPK1; PTGS2; HIF1A; EGFR; NFKB1; AR; CDK6; CDK2; ABL1; BCL2; AKT1; MAPK1; MET; TP53 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 9.612E-11 | 4.854E-09 | HSD11B1; HSD11B2; HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.871E-09 | 1.455E-07 | GSK3B; AR; CDK2; BCL2; AKT1; MAPK1; TP53; EGFR; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.042E-09 | 1.455E-07 | CYP2C9; PLA2G1B; ALOX5; ALOX15; TBXAS1; ALOX12; CYP2C19; PTGS2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.974E-08 | 4.430E-07 | CASP7; PARP1; LMNA; BCL2; AKT1; MAPK1; ATM; TP53; NFKB1; MCL1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 9.474E-09 | 2.392E-07 | PKM; FLT3; AKT1; MAPK1; TP53; MET; HIF1A; EGFR |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.656E-08 | 4.878E-07 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.730E-08 | 6.278E-07 | CYP2C9; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS2 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.477E-07 | 3.088E-06 | GSK3B; SYK; BRCA1; EGFR; NFKB1; CDK6; CDK2; BCL2; AKT1; MAPK1; TP53; MET; MCL1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 6.805E-08 | 9.818E-07 | GSK3B; ABL1; BCL2; AKT1; MAPK1; PTPN11; MAPK14; TP53; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.785E-08 | 7.435E-07 | HSD11B1; CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.493E-07 | 3.697E-06 | GSK3B; AKT1; MAPK1; MAPK14; ESR1; NFKB1; ESR2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.340E-08 | 4.726E-07 | CYP2C9; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.599E-07 | 3.088E-06 | CYP2C9; MAOA; CYP2D6; CYP1A2; AOX1; CYP3A4; CYP2C19 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.843E-07 | 3.697E-06 | CDK6; ABL1; AKT1; MAPK1; PTPN11; TP53; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.786E-07 | 2.406E-06 | ALDH2; MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.170E-07 | 3.557E-06 | SLCO1B1; CA2; SLCO1B3; NR1H4; CYP3A4; CFTR; ABCG2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.843E-07 | 3.697E-06 | HSD11B1; CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 9.241E-07 | 8.485E-06 | ABCC1; ADORA3; BCL2; AKT1; MAPK1; MAPK14; TP53; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.507E-06 | 2.624E-05 | PIM1; BCL2; AKT1; MAPK1; MAPK14; F3; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.185E-06 | 1.040E-05 | CDK6; CDK2; BCL2; AKT1; PTGS2; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 2.380E-06 | 1.923E-05 | GSK3B; CDK6; CSNK2A1; CDK2; AKT1; RAB9A; TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.043E-06 | 2.816E-05 | CDK6; CDK2; BCL2; AKT1; PTK2B; MAPK1; TP53; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 5.662E-06 | 3.588E-05 | AKT1; MAPK1; PTPN11; MAPK14; TP53; HIF1A; ESR1; MET; EGFR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 5.440E-06 | 3.588E-05 | GSK3B; SYK; CSNK2A1; CDK2; BCL2; AKT1; MAPK14; TP53; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.014E-06 | 1.695E-05 | SYK; CSNK2A1; PARP1; BCL2; ATM; PTGS2; NFKB1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 7.250E-06 | 4.438E-05 | THPO; PIM1; BCL2; AKT1; AOX1; PTPN11; PTPN2; MCL1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.699E-06 | 2.669E-05 | CDK6; AKT1; MAPK1; TP53; EGFR; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.380E-06 | 2.624E-05 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; AOX1; CYP3A4 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 5.683E-06 | 3.588E-05 | CDK6; AKT1; MAPK1; TP53; MET; EGFR |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.148E-05 | 1.205E-04 | GSK3B; AKT1; MAPK1; MAPK14; TP53; EGFR; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.362E-05 | 8.092E-05 | GSK3B; CDK6; CDK2; ABL1; ATM; TP53; CDC25B |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 4.747E-05 | 2.316E-04 | POLB; CDK6; PKM; SYK; CDK2; MAPK1; TP53; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 9.693E-05 | 4.112E-04 | PLA2G1B; ABL1; AKT1; MAPK1; PTPN11; MET; EGFR; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.815E-05 | 2.316E-04 | BCL2; AKT1; MAPK1; HIF1A; EGFR; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 6.959E-05 | 3.056E-04 | CASP7; AKT1; MAPK1; MAPK14; PTGS2; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.706E-05 | 1.478E-04 | CDK6; AKT1; MAPK1; TP53; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.879E-05 | 1.084E-04 | GSK3B; AKT1; MAPK1; TP53; EGFR |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.226E-04 | 4.675E-04 | GSK3B; CASP1; AKT1; MAPK1; PLG; MAPK14; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.952E-05 | 1.569E-04 | FLT3; PIM1; AKT1; MAPK1; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.028E-04 | 4.130E-04 | GSK3B; AKT1; MAPK1; TP53; ESR1; HIF1A |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.028E-04 | 4.130E-04 | ALOX5; BCL2; AKT1; MAPK1; MAPK14; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 5.593E-05 | 2.628E-04 | CDK6; AKT1; MAPK1; TP53; EGFR |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.153E-04 | 7.630E-04 | AKT1; MAPK1; MAPT; MAPK14; TP53; EGFR; NFKB1; CDC25B |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 4.449E-05 | 2.247E-04 | GSK3B; BCL2; AKT1; MAPK1; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.461E-04 | 5.364E-04 | HPGD; KMT2A; FLT3; ATM; TP53; MET; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 9.771E-05 | 4.112E-04 | GSK3B; SYK; AKT1; MAPK1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 6.022E-05 | 2.764E-04 | AKT1; MAPK1; PTPN11; MET; HIF1A |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.981E-04 | 7.144E-04 | CDK2; AKT1; MAPK1; ATM; MAPK14; EGFR |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 3.043E-04 | 1.024E-03 | SYK; AKT1; PTK2B; MAPK1; PTPN11; EGFR |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 6.953E-05 | 3.056E-04 | PTPN11; MAPK14; MET; EGFR; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 3.898E-04 | 1.270E-03 | CDK2; AKT1; MAPK1; MAPK14; CDC25B |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.241E-04 | 7.804E-04 | GSK3B; ABL1; AKT1; MAPK1; EGFR |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.043E-04 | 4.130E-04 | PTPN1; CSNK2A1; MAPK1; MET; EGFR |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 6.681E-04 | 1.985E-03 | ADORA3; AKT1; MAPK1; PDE5A; ADRA2C; ADRA2A |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.084E-04 | 1.310E-03 | AKT1; MAPK1; ESR1; EGFR; ESR2 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.112E-04 | 4.318E-04 | CASP7; CASP1; MAPK1; MAPK14; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 5.122E-04 | 1.592E-03 | GSK3B; AKT1; MAPK1; MAPK14; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 6.346E-04 | 1.913E-03 | PTPN1; GSK3B; AKT1; PTPN11; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 9.315E-04 | 2.650E-03 | SYK; BCL2; AKT1; MAPK1; MAPK14; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.055E-03 | 2.920E-03 | SYK; TBXAS1; AKT1; MAPK1; MAPK14 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.779E-03 | 4.492E-03 | GSK3B; BCL2; AKT1; MAPK1; MET; EGFR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.649E-03 | 4.218E-03 | HCAR2; AKT1; MAPK1; CFTR; NFKB1; TSHR |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.498E-03 | 3.880E-03 | SYK; AKT1; MAPK1; MAPK14; NFKB1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.065E-03 | 5.149E-03 | GSK3B; ESRRB; AKT1; MAPK1; MAPK14 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 4.253E-03 | 9.545E-03 | GSK3B; CASP7; MAPK1; MAPT; HSD17B10 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 5.912E-03 | 1.244E-02 | POLB; GSK3B; AKT1; ATM; TP53; NFKB1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 8.260E-03 | 1.652E-02 | ADORA3; NMUR2; PLG; ADRA2C; ADRA2A; TSHR |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 6.365E-03 | 1.312E-02 | CSNK2A1; CDK2; PTPN11; TP53; NFKB1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 8.957E-04 | 2.585E-03 | SYK; AKT1; MAPK1; MAPK14 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.631E-03 | 6.402E-03 | PTK2B; MAPK1; MAPK14; EGFR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.830E-03 | 8.791E-03 | AKT1; MAPK1; HIF1A; EGFR |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 4.549E-03 | 1.010E-02 | AKT1; MAPK1; MAPK14; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 4.251E-03 | 9.545E-03 | AKT1; MAPK1; MAPK14; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 6.655E-03 | 1.344E-02 | GSK3B; AKT1; PTK2B; MAPK1; NFKB1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 5.354E-03 | 1.138E-02 | ACHE; BCL2; AKT1; MAPK1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.088E-02 | 2.035E-02 | AKT1; MAPK1; MAPK14; MET; EGFR |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.938E-04 | 1.817E-03 | AKT1; MAPK1; MAPK14; PTGS2 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.055E-02 | 1.991E-02 | SYK; PTK2B; MAPK1; PTPN11 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.437E-02 | 2.592E-02 | BCL2; AKT1; MAPK1; MAPK14 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.537E-02 | 2.747E-02 | GSK3B; CASP7; AKT1; NFKB1 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 8.557E-03 | 1.695E-02 | GSK3B; ABL1; MAPK1; MET |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 9.029E-03 | 1.771E-02 | GSK3B; MAOA; AKT1; MAPK14 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.169E-03 | 3.147E-03 | MAPK1; MAPK14; PTGS2; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.164E-02 | 2.158E-02 | PTPN1; GSK3B; AKT1; MAPK1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.141E-03 | 5.274E-03 | CASP1; MAPK1; MAPK14; NFKB1 |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 9.462E-04 | 2.655E-03 | CDK6; CDK2; ATM; TP53 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.536E-02 | 4.306E-02 | GSK3B; MAPK1; TYR |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 7.555E-04 | 2.212E-03 | ABL1; MAPK1; MAPK14; NFKB1 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.101E-02 | 3.690E-02 | SYK; AKT1; MAPK1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 4.582E-04 | 1.446E-03 | CASP1; MAPK1; MAPK14; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 2.160E-02 | 3.762E-02 | AKT1; TP53; NFKB1 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 2.602E-02 | 4.381E-02 | MAPK1; MAPK14; PTGS2 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 2.282E-02 | 3.940E-02 | CA2; PLA2G1B; CFTR |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 2.985E-04 | 1.022E-03 | BCL2; CASP1; MAPK14; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.625E-05 | 1.878E-04 | MGAM; AKR1B10; GAA; AKR1B1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.270E-04 | 4.750E-04 | DAPK1; MAPK1; TP53; EGFR |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 9.833E-03 | 1.892E-02 | AKT1; PTPN11; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.306E-03 | 1.138E-02 | AKT1; PTGS2; TSHR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 6.433E-03 | 1.312E-02 | AKT1; MAPK1; HIF1A |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 5.045E-03 | 1.108E-02 | CASP7; CASP1; NFKB1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 6.139E-03 | 1.278E-02 | AKR1B10; ALDH2; AKR1B1 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 5.306E-03 | 1.138E-02 | MGAM; AGL; GAA |
| hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 3.434E-03 | 7.973E-03 | ALDH2; AOX1; HSD17B10 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 3.042E-03 | 7.228E-03 | CYP3A4; XDH; CES2 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.678E-03 | 6.440E-03 | ABCC1; CFTR; ABCG2 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.507E-02 | 4.291E-02 | HSD11B2; MAPK1 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.379E-03 | 3.666E-03 | MAOA; AOX1; TYR |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 2.628E-02 | 4.387E-02 | PKM; ALDH2 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.160E-03 | 3.147E-03 | POLB; PARP1; APEX1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.498E-03 | 3.880E-03 | AKR1B10; ALDH2; AKR1B1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.431E-02 | 2.592E-02 | MAPK1; TP53 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.247E-02 | 2.290E-02 | MAPK1; EGFR |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.726E-02 | 3.059E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 9.136E-03 | 1.775E-02 | CA2; CA4 |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 9.926E-03 | 1.892E-02 | ALDH2; MAOA |
| hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 3.410E-03 | 7.973E-03 | ALPL; ALPI |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.889E-04 | 1.270E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; HCAR2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | PDE5A; PDE5A; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ALDH2; ADRA2C |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; HSD11B1; AKR1B1; MGAM; PTPN1; GSK3B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; PLA2G1B; ESRRA; ALOX5; ALOX5; SYK; SYK; PDE5A; PTGS2; ADRA2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; ADRA2C; PLG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; ADRA2C; CA4; CA4 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| NA: NA | HIV infections | NA | AHR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; F3; PTGS2; EGFR; AKT1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; ACHE; PTGS2; PTGS2; PTGS2; PTGS2; ADRA2C; ADRA2A; ESR1 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3; EGFR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PDE5A; FLT3; EGFR; EGFR; TP53 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1; PDE5A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; ACHE; CYP3A4 |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; ESR1 |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; EGFR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR; PARP1 |
| H60-H95: Diseases of the ear and mastoid process | Otitis media | H65-H67 | PLG |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Heart attack | NA | PLG |
| A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | PDE5A; PDE5A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; ABL1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| NA: NA | Acute coronary thrombosis | NA | PLG |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Excessive bleeding | R58 | PLG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Excessive postoperative bleeding | R58 | PLG |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ALDH2; ADORA3; EGFR; PARP1; PLG |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; BCL2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; PDE5A; MAPK14 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR; BCL2 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; ALOX5; HCAR2 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM; GAA |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3; CA9; CYP19A1; EGFR; EGFR; EGFR; BCL2; ESR1; ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| NA: NA | Inflammatory diseases | NA | MAPK14 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; PLG |
| C00-D49: Neoplasms | Thymoma | C37, D15.0 | CDK2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; ALOX5; SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; MGAM; PDE5A; HCAR2 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; MET; MCL1; CSNK2A1; SYK; CA1; FLT3; FLT3; CA9; ABL1; ACHE; PTGS2; CDK2; GSK3B; ADORA3; HIF1A; MAPK1; MAPK14; NFKB1; EGFR; PIM1; PARP1; CDC25B; PLG; BCL2; BCL2; TP53; ESR1; ESR1; AKT1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; PTGS2; PTGS2; MAPK14 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; GPBAR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ESRRA; ALOX5; SYK; CASP1; PTGS2; PTGS2; PTGS2; PTGS2; MAPK14; TYR |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| I00-I99: Diseases of the circulatory system | Chronic angina | I20 | PLG |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; HSD11B2; TBXAS1; MGAM; PTPN1; PTPN1; PTGS2; NFKB1; GPBAR1; HCAR2 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| NA: NA | Male hypogonadism | NA | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; HCAR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; PARP1; TYR |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; PKM; SYK; FLT3; CA9; ABL1; CDK2; HIF1A; MAPK1; EGFR; TP53; AKT1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | PDE5A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; EGFR; EGFR; EGFR; TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1; PLG; PLG; PLG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; MAPK14; EGFR; BCL2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ABL1; EGFR; BCL2; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | PLG; ESR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; ADORA3 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; TP53; TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; ABL1; CDK2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A; EGFR; BCL2; AKT1 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | PLG |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| I00-I99: Diseases of the circulatory system | Pulmonary embolism | I26 | PLG |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADORA3; ADRA2C |
| NA: NA | GIST | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2; ADORA3 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1; PTGS2; MAPK14 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B; ALOX5; SYK; PTGS2; MAPK14 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; ADRA2C |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; PTGS2; CDK2; ATM; EGFR; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; ESRRA |
| NA: NA | Raynaud's disease | NA | PDE5A; PDE5A |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2; MAPK14 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1; PTK2B |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ABL1; BCL2; ESR1; AKT1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | PLG |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |